Nerves Play Key Role In Triggering Prostate Cancer And Influencing Its Spread

BRONX, N.Y., July 11, 2013 /PRNewswire-USNewswire/ -- Researchers at Albert Einstein College of Medicine of Yeshiva University have found that nerves play a critical role in both the development and spread of prostate tumors. Their findings, using both a mouse model and human prostate tissue, may lead to new ways to predict the aggressiveness of prostate cancer and to novel therapies for preventing and treating the disease. The study published online today in the July 12 edition of Science.

Prostate cancer is second to skin cancer as the most common cancer in men. The National Cancer Institute estimates that 238,590 new cases of prostate cancer will be diagnosed in 2013, and 29,720 men will die from the disease.

Nerves are commonly found around tumors, but their role in the growth and progression of cancer has not been clear. "Since there might be similarities between the hematopoeitic stem cell niche and the stem cell niches found in cancer, we thought that sympathetic nerves might also have a role in tumor development," said Dr. Frenette. "It turns out that in prostate cancer, not only are sympathetic nerves involved, but so too are parasympathetic nerves."

The body's autonomic nervous system (governing functions that we don't consciously control, such as heart rate) is divided into two branches. The sympathetic nervous system, or SNS, modulates the body's "fight or flight response" by, for example, revving up the heart rate and constricting blood vessels. The parasympathetic nervous system, or PNS, generally acts in opposition to the SNS to keep bodily functions in balance.

The researchers discovered the role of nerves in prostate cancer by first injecting human prostate cancer cells into mice and then systematically disabling various parts of the SNS and PNS and observing how the cells fared. A control group of mice were administered the cancer cells but underwent no further interventions.

The study found that the autonomic nervous system's two branches have complementary functions in the development and spread of prostate cancer. The SNS helps initiate the early phases of the disease, while the PNS is involved in the later stages when the cancer spreads.

More specifically, the researchers found that the SNS promotes tumor growth by producing the neurotransmitter norepinephrine, which then binds to and stimulates two types of adrenergic receptors (beta-2 and beta-3) on the surface of the stromal cells in the tumor (adrenergic receptors are targeted by adrenaline and noradrenaline, also known respectively as epinephrine and norepinephrine). "This is consistent with recent epidemiological studies showing that the use of beta-blockers, which lower blood pressure by blocking beta-adrenergic receptors, is associated with improved survival of prostate cancer patients," said Dr. Frenette.

As for the PNS's role in cancer progression, it makes tumor cells invade other tissues and travel to distant parts of the body (tumor metastasis) when its nerve fibers release acetylcholine, which activates a signaling pathway in stromal cells of the tumor microenvironment. (Stromal cells make up connective tissue.)

"Our findings raise the tantalizing possibility that drugs targeting both branches of the autonomic nervous system may be useful therapies for prostate cancer," Dr. Frenette added.

To see whether their findings were relevant to human cancer, the researchers analyzed nerve fiber densities in prostate tissue specimens taken from 43 patients with prostate cancer who had not undergone any treatment.

Patients who turned out to have aggressive prostate cancers had a higher density of nerve fibers within tumors and in normal prostate tissue surrounding their tumors compared with patients who had less aggressive tumors. "More work needs to be done, but the findings suggest that nerve density assessment merits further study as a possible predictive marker of prostate cancer aggressiveness," said Dr. Frenette.

Whether these findings apply to other forms of cancer is uncertain. "Clinical studies show that breast cancer patients who took beta blockers did better than those who were not taking beta blockers," said Dr. Frenette. "This suggests that the same mechanisms are involved, but that remains to be seen."

The study was supported by an Idea Development award from the Department of Defense (W81XWH-07-1-0165) and grants from the National Institutes of Health.

Albert Einstein College of Medicine has a pending U.S. patent application relating to the use of adrenergic and muscarinic receptors antagonists for cancer therapy, which is currently available for licensing.

About Albert Einstein College of Medicine of Yeshiva University

Albert Einstein College of Medicine of Yeshiva University is one of the nation's premier centers for research, medical education and clinical investigation. During the 2012-2013 academic year, Einstein is home to 742 M.D. students, 245 Ph.D. students, 116 students in the combined M.D./Ph.D. program , and 360 postdoctoral research fellows. The College of Medicine has more than 2,000 full-time faculty members located on the main campus and at its clinical affiliates. In 2012, Einstein received over $160 million in awards from the NIH. This includes the funding of major research centers at Einstein in diabetes, cancer, liver disease, and AIDS. Other areas where the College of Medicine is concentrating its efforts include developmental brain research, neuroscience, cardiac disease, and initiatives to reduce and eliminate ethnic and racial health disparities. Its partnership with Montefiore Medical Center , the University Hospital and academic medical center for Einstein, advances clinical and translational research to accelerate the pace at which new discoveries become the treatments and therapies that benefit patients. Through its extensive affiliation network involving Montefiore, Jacobi Medical Center Einstein's founding hospital, and five other hospital systems in the Bronx, Manhattan, Long Island and Brooklyn, Einstein runs one of the largest residency and fellowship training programs in the medical and dental professions in the United States. For more information, please visit www.einstein.yu.edu, read our blog, follow us on Twitter, like us on Facebook, and view us on YouTube.